Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission.
Alaska Native
autoimmune hepatitis
overlap syndrome
prevalence
remission
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
27
03
2023
revised:
22
06
2023
accepted:
05
07
2023
medline:
31
8
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
High autoimmune hepatitis (AIH) and overlap syndrome (OS) prevalence have been previously documented among Alaska Native people. The purpose of this project is to report changes in AIH/OS prevalence over time, clinical characteristics, and factors associated with biochemical remission. We reviewed medical records for Alaska Native/American Indian (AN/AI) patients diagnosed with AIH/OS between 1984 and 2021. Point prevalence was calculated based on AIH/OS patients alive at the end of 2021 and at 5-year intervals from July 1, 2000, to July 1, 2020. We identified 189 AN/AI persons diagnosed with AIH or OS (157 AIH, 32 OS). Of these 189, 137 were alive at the end of 2021 for a point prevalence of 91.2 per 100 000 (95% confidence interval [CI]: 77.2-107.8)-75.9 (95% CI: 63.2-91.2) for AIH and 15.3 (95% CI: 10.2-23.0) for OS. Prevalence for both AIH and OS has risen steadily since 2000. Eighty-nine consented participants (62.7%) achieved biochemical remission with a median time from diagnosis to start of remission of 1.9 years (IQR 0.5-5.0 years). Consented patients with fatty liver were less likely to achieve remission, but their time to remission was shorter than for patients without fatty liver. The AN/AI population in Alaska continues to have the highest reported prevalence of AIH/OS in the world, with prevalence rising steadily since 2000. High reported AIH/OS prevalence is likely due in part to strong referral networks for liver disease. Detection and treatment can lead to biochemical remission and improved health outcomes.
Sections du résumé
Background and Aim
UNASSIGNED
High autoimmune hepatitis (AIH) and overlap syndrome (OS) prevalence have been previously documented among Alaska Native people. The purpose of this project is to report changes in AIH/OS prevalence over time, clinical characteristics, and factors associated with biochemical remission.
Methods
UNASSIGNED
We reviewed medical records for Alaska Native/American Indian (AN/AI) patients diagnosed with AIH/OS between 1984 and 2021. Point prevalence was calculated based on AIH/OS patients alive at the end of 2021 and at 5-year intervals from July 1, 2000, to July 1, 2020.
Results
UNASSIGNED
We identified 189 AN/AI persons diagnosed with AIH or OS (157 AIH, 32 OS). Of these 189, 137 were alive at the end of 2021 for a point prevalence of 91.2 per 100 000 (95% confidence interval [CI]: 77.2-107.8)-75.9 (95% CI: 63.2-91.2) for AIH and 15.3 (95% CI: 10.2-23.0) for OS. Prevalence for both AIH and OS has risen steadily since 2000. Eighty-nine consented participants (62.7%) achieved biochemical remission with a median time from diagnosis to start of remission of 1.9 years (IQR 0.5-5.0 years). Consented patients with fatty liver were less likely to achieve remission, but their time to remission was shorter than for patients without fatty liver.
Conclusion
UNASSIGNED
The AN/AI population in Alaska continues to have the highest reported prevalence of AIH/OS in the world, with prevalence rising steadily since 2000. High reported AIH/OS prevalence is likely due in part to strong referral networks for liver disease. Detection and treatment can lead to biochemical remission and improved health outcomes.
Identifiants
pubmed: 37649864
doi: 10.1002/jgh3.12946
pii: JGH312946
pmc: PMC10463022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
545-552Informations de copyright
© 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
World J Gastroenterol. 2016 May 21;22(19):4651-61
pubmed: 27217697
J Rheumatol. 1991 Oct;18(10):1477-84
pubmed: 1765971
J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):903-910
pubmed: 33074948
Am J Epidemiol. 1977 Feb;105(2):118-22
pubmed: 835563
J Clin Gastroenterol. 2010 Mar;44(3):208-13
pubmed: 20087196
Clin Res Hepatol Gastroenterol. 2022 Jan;46(1):101761
pubmed: 34325013
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Med Sci Monit. 2017 Oct 26;23:5106-5112
pubmed: 29073121
Arthritis Rheumatol. 2014 Sep;66(9):2494-502
pubmed: 24891315
Pathologica. 2021 Jun;113(3):185-193
pubmed: 34294936
Dig Liver Dis. 2019 Sep;51(9):1294-1299
pubmed: 30850346
World J Gastroenterol. 2008 Jun 7;14(21):3368-73
pubmed: 18528934
World J Gastroenterol. 2015 Jan 7;21(1):60-83
pubmed: 25574080
Am J Gastroenterol. 2002 Sep;97(9):2402-7
pubmed: 12358264
Arthritis Care Res (Hoboken). 2012 Jan;64(1):138-43
pubmed: 21972194
Hepatology. 2020 Aug;72(2):671-722
pubmed: 31863477
J Gastroenterol Hepatol. 2010 Oct;25(10):1681-6
pubmed: 20880179
Am J Epidemiol. 1993 Oct 1;138(7):544-9
pubmed: 8213758
J Hepatol. 2014 Mar;60(3):612-7
pubmed: 24326217
J Immunol Res. 2019 Nov 25;2019:9437043
pubmed: 31886312
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
J Gastroenterol Hepatol. 2019 Oct;34(10):1676-1684
pubmed: 31146297
PLoS One. 2017 Aug 3;12(8):e0182391
pubmed: 28771543
J Gastroenterol Hepatol. 2001 Dec;16(12):1384-9
pubmed: 11851837